31
Mar
2008
Keeping Up With HB08-1001
Posted in My Rants
It has been incredibly exciting to observe the legislative process for HB1001, the Bill that may bring north of $25M to the Colorado life science ecosystem over the next five years. The Bill has marched through the House and has been working its way through the Senate passing unamended in the Appropriations committee last Friday. [...]
31
Mar
2008
And the BioBeers beat marches on in March at the Milwaukee Street Tavern. Do you speak Cherry Creek? That’s right the Colorado BioBeers tour continues, pulling in next to the Milwaukee Street Tavern station, TONIGHT 31 March 7:30pm. This month we are including FREE name tags! Bonus! And suitable for framing too after the event.
It [...]
31
Mar
2008
ARCA Discovery has changed their name to ARCA Biopharma. The modification in moniker more appropriately correlates with the enterprises graduation from a discovery to now a commercialization focus as demonstrated by a planned 2008 NDA filing with the FDA. A beautiful new website and logo has been rolled out as well. Take a look (here). [...]
28
Mar
2008
Ventrus Biosciences, a specialty pharmaceutical company based in Greenwood Village, focused on the late-stage development and commercialization of gastrointestinal products, and Sam Amer & Co. (who I need to dig up some additional info on – a simple google search yields nada…) announced an agreement granting Ventrus exclusive world wide rights to develop and commercialize [...]
27
Mar
2008
Congratulations to Assistant Professor Hang (Hubert) Yin, University of Colorado at Boulder Department of Chemistry and Biochemistry who has received the Kimmel Scholar Award from the Sidney Kimmel Foundation for Cancer Research. Dr. Yin is the first CU Boulder researcher to accept the prestigious award.
The Sidney Kimmel Foundation for Cancer Research funds the Kimmel Scholars [...]
26
Mar
2008
The Workforce Innovation Grant II RFP has been announced. The program seeks to address specific industry needs by funding innovative workforce development, training, entrepreneurship, and other industry-specific education and training partnership projects that directly lead to employment or employee advancement in bioscience.
For eligibility and additional information click (here).
Note: the mandatory Pre-Proposal Conference will be held [...]
25
Mar
2008
It appears as though the link broke in yesterday’s RSS feed for the Boulder Biotechnology Company Tree .pdf.
Here is the link: http://ab.rubenstein.googlepages.com/boulderbiotechtreeoct07
My apologies for any frustrations and a hearty thank you to the ever vigilant wonder-attorney Jeff Bojar, JD, MS of Snell & Wilmer who pointed out the error to me.
This provides me an opportunity [...]
25
Mar
2008
It’s a GlobeImmune kind of day…How exciting to see Dr. Freytag join the GI Board of Directors. Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Aspreva Pharmaceuticals Company from July 2007 through December 2007 when Aspreva was acquired by Galenica for approximately $915 million. He held the same positions [...]
25
Mar
2008
GlobeImmune initiated a Phase IIa trial to evaluate their GI-4000 Tarmogen® for the treatment of non-small cell lung cancer (NSCLC) patients with tumors having mutations in the ras gene. NSCLC patients with tumors positive for mutated ras may have a worse survival compared to patients with other NSCLC types and therefore these patients may not [...]
24
Mar
2008
You may have seen this impressive Boulder Biotechnology Company Tree document before, perhaps even here on the CLSDF side-bar; click (here) for the .pdf. For those of you who have not previously taken a look be prepared to 1) be wow-ed and 2) have the point driven home on what an incredibly robust trajectory Boulder [...]
21
Mar
2008
…To a deluxe apartment, wait, make that a deluxe new office in the sky. ARCA Discovery is currently headquartered in LoDo, the labs however at last check remain at the Colorado Science + Technology Park @ Fitzsimons and, I would venture to guess shall remain there as plans are finalized to make the move north [...]
20
Mar
2008
It is often a challenging path to be first to market. Insmed (NASDAQ: INSM) is blazing that trail via their aim to be the first US-based biotechnology company to develop a comprehensive portfolio of Follow-on Biologics (FOBs). From my understanding, one such challenge the company faces is that no regulatory pathway currently exists for FOBs, [...]
19
Mar
2008
The blogosphere is an amazing place, enabling the cultivation of rich relationships that may otherwise never come to pass. One such contact I have been lucky enough to cultivate is with Yali Friedman, Ph.D. the founder of thinkBiotech and author of Building Biotechnology and the BioTechBlog.
Yali’s newest work released today is Best Practices in Biotechnology [...]
Life Science Deal Flow PARTNERS
-
